Universität zu Köln

El Majdoub, F., Simon, T., Hoevels, M., Berthold, F., Sturm, V. and Maarouf, M. (2011). Interstitial Brachytherapy using Stereotactic Implanted (125)Iodine Seeds for Recurrent Medulloblastoma. Clin. Oncol., 23 (8). S. 532 - 538. LONDON: ELSEVIER SCIENCE LONDON. ISSN 0936-6555

Full text not available from this repository.

Abstract

Aims: To evaluate the efficacy of interstitial brachytherapy using (125)iodine (I-125) seeds for the treatment of recurrent multimodal treated medulloblastoma. Materials and methods: Between September 1989 and August 2009, 12 patients (female:male = 3:9, median age 19 years, range 7-55 years) with 23 recurrent medulloblastomas underwent interstitial brachytherapy using I-125 seeds. Before brachytherapy, all patients underwent microsurgical resection; six patients underwent a combined adjuvant treatment consisting of craniospinal irradiation and chemotherapy; three received craniospinal irradiation alone and two received chemotherapy alone. One patient was treated by surgery alone. The median tumour volume was 4.9 ml (range 0.4-44.2 ml), the median tumour surface dose 50 Gy (range 32-50 Gy) and the median implantation time 42 days (range 42-90 days). A median follow-up of 26 months was available (range 5-116 months). Results: After brachytherapy, nine of 23 tumours (39%) presented a complete remission, nine (39%) a partial remission and five (22%) stable disease on magnetic resonance images. The neurological status improved in six patients and remained unchanged in four. Two patients deteriorated: one developed spinal metastasis and another a treatment-related adverse radiation effect. Ten patients died due to disseminated disease despite local tumour control. The median survival after treatment was 15 months (range 5-68 months). Conclusions: Our results show a good response of recurrent medulloblastoma after interstitial brachytherapy. High rates of tumour remission were yielded with low rates of treatment-related morbidity. Thus, I-125 seed brachytherapy should be considered as a treatment option for recurrent medulloblastoma. (C) 2011 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code El Majdoub, F. UNSPECIFIED UNSPECIFIED UNSPECIFIED Simon, T. UNSPECIFIED UNSPECIFIED UNSPECIFIED Hoevels, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Berthold, F. UNSPECIFIED UNSPECIFIED UNSPECIFIED Sturm, V. UNSPECIFIED UNSPECIFIED UNSPECIFIED Maarouf, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-488095
DOI:	10.1016/j.clon.2011.02.009
Journal or Publication Title:	Clin. Oncol.
Volume:	23
Number:	8
Page Range:	S. 532 - 538
Date:	2011
Publisher:	ELSEVIER SCIENCE LONDON
Place of Publication:	LONDON
ISSN:	0936-6555
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language HIGH-DOSE CHEMOTHERAPY; I-125 RADIOSURGERY; PROGNOSTIC-FACTORS; POSTERIOR-FOSSA; BRAIN-TUMORS; NECK-CANCER; MANAGEMENT; ADULTS; RADIOTHERAPY; CHILDHOOD Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/48809